What Happened?
Amherst, MA-based University of Massachusetts Medical School has Appointed Gregory R. Wolf as Chief Information Officer
About the Company
The University of Massachusetts Medical School (UMMS), the state`s first and only public academic health sciences center, focuses on enhancing the health and well-being of the people of the commonwealth and the world through pioneering innovations in education, research and health care delivery. UMMS is one of the fastest-growing research institutions in the country! We educate physicians, scientists and advanced practice nurses to heal, discover, teach and care, with compassion. UMMS is a world-class institution that was ranked #5 in 2014 as one of the leading medical schools in the nation for primary care education by U.S. News & World Report. The institution ranks near the top among public medical schools in the Northeast in the amount of funding awarded by the National Institutes of Health (NIH). Commonwealth Medicine and MassBiologics are business units of UMMS that help us provide services and programs to meet the needs of the public. Commonwealth Medicine (CWM) is the health care consulting arm of University of Massachusetts Medical School (UMMS). CWM provides a wide range of care management and consulting services to government agencies, nonprofits, and health care organizations, helping them meet today`s health care challenge. CWM is dedicated to improving health care for people in need – while also controlling costs and maximizing revenue for our clients and performing cutting edge research that impacts health policy. MassBiologics (MBL) is a business unit of University of Massachusetts Medical School (UMMS) and the only non-profit, FDA-licensed manufacturer of vaccines in the United States. MBL discovers and develops products that significantly improve public health and create medicine for better lives around the world. MBL improves public health through applied research, development and production of biologic products, including vaccines, plasma derivatives and monoclonal antibodies.
About the Person
Gregory R. Wolf is executive director of research computing platforms at the Novartis Institutes for Biomedical Research (NIBR) in Cambridge
Info Source
News
Short Profile